Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

12 June 2026

RTW Biotech Opportunities Ltd

Monthly Valuation Update and Factsheet

RTW Biotech Opportunities Ltd (the "Company") announces that its monthly factsheet and commentary as at 31 May 2026 is now available at https://www.rtwbio.com/factsheets-letters/.

The Company's unaudited net asset value attributable to its ordinary shares as at 31 May 2026 was US$2.61 per share, an increase of +0.6% from the previous month vs +2.3% for the Nasdaq Biotech Index and +6.1% for the Russell 2000 Biotech Index. The Company has delivered +14.4% annualised NAV per ordinary share performance since launch in October 2019. 

Top 10 Positions

Top YTD Contributors and Detractors

Note: % NAV as at period end reflects gross economic exposure as a percentage of NAV.

COMPANY UPDATE

RTW Bio's Annual General Meeting was held at 2pm BST on 11 June 2026. We are pleased to announce that each of the resolutions was duly passed without amendment.

RTW Bio continued to make market purchases of its Ordinary Shares under the authority granted by shareholders at its Annual General Meeting in June 2025. RTW Bio repurchased 8.4 million shares (equivalent to $14.0 million), over the twelve months to 31 May 2026. The discount to NAV at which RTW Bio's Ordinary Shares trade has closed from 32.5% to 15.6% over the same period.

SECTOR UPDATE

Biotech sector sentiment improved materially in the second half of May, driven by strong first-quarter earnings from commercial-stage companies, continued M&A activity and a slate of positive clinical readouts. Despite this, sector funds recorded outflows of approximately $2 billion year-to-date through May.

Following an exceptionally strong April, capital markets activity was moderate during the month, with one IPO and 18 follow-on transactions. M&A activity remained strong, with six transactions announced in May, four of which involved private companies, consistent with the continuing strategic appetite of large-cap pharma facing near-term patent expiries.

FDA Commissioner Marty Makary resigned from his role in May - a development broadly welcomed by biotech, given the widening disconnect between his stated pro-innovation agenda and the agency's actions in practice. Kyle Diamantas, previously the agency's top food official, assumes the role in an acting capacity. A permanent appointment will require congressional hearings, which could take some time. Regulatory continuity remains a topic the sector is watching.

Political scrutiny of US-China biotech ties intensified in May, with lawmakers pressing the Trump administration to restrict Chinese biotech partnerships. Large pharma deals involving Chinese assets nonetheless continued, with significant transactions announced by Pfizer and Bristol Myers Squibb. Our long-standing coverage of and presence in China positions us well to identify investments and drug candidates in an environment where the quality of Chinese biotech science is increasingly evident on the global stage.

ASCO 2026 in Chicago, a pre-eminent global oncology conference, featured an unusually strong slate of late-stage data. Portfolio companies presented results across several programmes: Celcuity presented Phase 3 results for gedatolisib in advanced breast cancer, more than doubling the time patients lived without disease progression compared to the current standard of care, and Immatics presented Phase 1 data for IMA203CD8 in heavily pre-treated ovarian cancer, achieving a 63% response rate including complete responses from a single infusion - a striking result given that this tumour type has historically resisted immunotherapy. You can read RTW's reflections on this year's conference on the RTW Thought Leadership page.

PORTFOLIO UPDATE - MAY

On 8 May, RTW Bio made an additional investment of $1.7 million in private portfolio company Windward Bio, as part of a $165 million crossover financing round. Windward is a clinical-stage biotechnology company focused on serious immunological diseases. Its lead programme, WIN378, is currently being evaluated in a Phase 2/3 asthma study, with initial readouts expected in the second half of 2026. If approved, it would be the first ultra long-acting treatment of its type available to patients. As at 31 May 2026, Windward represented 0.8% of RTW Bio's NAV.

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********